You are here: Industry Insights > Onureg

News List

Bristol Myers Squibb Receives European Commission Approval for Onureg® as Oral Therapy for Adults with Leukemia americanpharmaceuticalreview
June 23, 2021
Bristol Myers Squibb announced that the European Commission (EC) has granted full Marketing Authorization for Onureg® (azacitidine tablets) as maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) ...
Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® for Adults with Acute Myeloid Leukemia in First Remission americanpharmaceuticalreview
April 26, 2021
Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Onureg® (azacitidine tablets; CC-486) as a maintenance therapy in adult patients with ...
FDA Approves Onureg (azacitidine tablets) as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia drugs.com
September 23, 2020
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Onureg (azacitidine 300 mg tablets.
US FDA approves Onureg (azacitidine tablets) to treat acute myeloid leukaemia expresspharma
September 03, 2020
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Onureg (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult patients with acute myeloid leukaemia (AML) ...